Analysts Set Lantheus Holdings, Inc. (NASDAQ:LNTH) Price Target at $129.43

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) has earned a consensus rating of "Buy" from the seven brokerages that are presently covering the company, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $129.43.

A number of brokerages recently weighed in on LNTH. JMP Securities restated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial upped their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Finally, B. Riley lowered their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 63,109 shares of company stock worth $6,016,046 in the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Lantheus

A number of large investors have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new position in Lantheus during the 3rd quarter worth approximately $25,000. Kestra Investment Management LLC purchased a new position in shares of Lantheus during the fourth quarter valued at $27,000. Summit Securities Group LLC acquired a new position in Lantheus during the fourth quarter valued at $37,000. UMB Bank n.a. lifted its stake in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after acquiring an additional 134 shares in the last quarter. Finally, World Investment Advisors LLC acquired a new stake in Lantheus during the 3rd quarter worth about $60,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Stock Performance

Shares of NASDAQ:LNTH traded down $1.87 during trading hours on Thursday, hitting $101.77. The stock had a trading volume of 644,509 shares, compared to its average volume of 955,167. The stock's fifty day simple moving average is $97.37 and its 200 day simple moving average is $95.23. The firm has a market capitalization of $6.97 billion, a price-to-earnings ratio of 16.93 and a beta of 0.20. Lantheus has a 1-year low of $65.76 and a 1-year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. As a group, research analysts anticipate that Lantheus will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.